|
|
Article: Biocon Limited Presents Human Clinical Data on IN-105 Oral Insulin at the EASD Meeting in Rome.
- Article from:
- Diabetes Week
- Article date:
- September 22, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Biocon Limited, India's premier biotechnology company, announced the results of an ascending dose study with their oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome on September 8, 2008. The study involved dosing Type 2 diabetes subjects with single doses of 0 mg (placebo), 10 mg, 15 mg, 20 mg and 30 mg tablets of IN-105 in 5 separate periods before a mixed 600 kcal breakfast. The outcome measurements were the safety and tolerability of IN-105, as well as the pharmacokinetics and pharmacodynamics of IN-105. The results showed that IN-105 was safe and well tolerated by patients (see also Biocon Limited).
...
Related newspaper, magazine, and journal articles:
|
|
Article: BIOCON LIMITED Consensus Recommendation: BUY.
TFN/Nelson's Research Reports;
October 20, 2008 ;
297 words
...Oct 20, 2008 (Nelson's Broker Summaries via COMTEX) -- Company: BIOCON LIMITED Consensus Recommendation: BUY (Strong Buy: 5, Buy: 2, Hold: 4, Underperform: 2, Sell: 1) Quarter Consensus Estimate ...
|
|